Skip to main content
. Author manuscript; available in PMC: 2015 Jul 15.
Published in final edited form as: Clin Cancer Res. 2014 May 16;20(14):3730–3741. doi: 10.1158/1078-0432.CCR-13-3446

Figure 4. Veliparib enhances the efficacy of TMZ in vivo in GBM12 but not in TMZ-resistant sub-lines.

Figure 4

A) Tumor regrowth analysis: Mice with established flank tumor xenografts were randomized into groups of 10 mice each and treated for 3 cycles with the indicated drugs. Time for reaching critical tumor volume of 1500 mm3 is shown as endpoint for each group as Kaplan-Meier plots. B) Pharmacodynamic analysis: mice with GBM12 or GBM12TMZ-mgmtHigh xenografts were treated for 5 days and euthanized either 2 hours or 72 hours after the last dose of TMZ/veliparib. Three tumors were processed for each treatment/time point, and equal amounts of protein from these tumors were pooled for analysis in any given lane. All samples were run on the same gel, but 2 unloaded intervening lanes have been cropped from the images, MW indicates molecular weight. C) Pharmacokinetic profile of veliparib in tumor tissue: Groups of mice with flank xenografts were treated for 5 days with TMZ/veliparib and euthanized at time-points ranging from 0 to 6 hours after the last dose of veliparib. The values plotted are the mean ± SD veliparib concentrations in 5 tumors at each time point.